
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is a biotechnology company with a strong financial position and promising drug pipeline. Their lead drug, SL-325, has shown a differentiated safety profile and superior blockade of inflammatory signaling, with a completion date for its clinical trial set in 2029. With potential for multiple indications and targeting of DR3, Shattuck Labs could be an appealing acquisition target for the future.
Bears say
Shattuck Labs is facing stiff competition and potential funding issues, which could slow down the development of their TL1A therapy. The expertise of the company's leadership is a positive factor, but ultimately, the success of their pipeline drugs will determine the stock's performance. With a projected price target of $15 based on risk-adjusted net present value analysis, there is not enough upside potential for investors to have a positive outlook on the stock.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares